Pharmacology

Loyal’s application for drug approval is another step closer to potential approval through the FDA Center for Veterinary Medicine.

Robenacoxib tablets from ZyVet Animal Health are bioequivalent to Onsior (Elanco Animal Health).

The product from Virbac contains ursolic acid that inhibits messenger RNA expression changes associated with muscle atrophy.

Zygolide by Dechra offers a generic, bioequivalent option for managing pituitary pars intermedia dysfunction in horses.

Advancements in drug therapies and a focus on the well-being of veterinary professionals were among the most viewed article topics on dvm360.com this year.

Felixvet's meloxicam oral suspension is bioequivalent to Metacam.

Virbac acquired an oral solution of methimazole, known as Felanorm in the US and Thyronorm outside the US. The drug is the first FDA-approved generic methimazole oral solution for hyperthyroidism in cats.

Credelio Quattro (Elanco) was previously approved by the FDA for treatment of infestation for 6 other parasites in dogs.

Elanco's monoclonal antibody therapy, Trutect, received a conditional license from the federal agency in 2023.

The platform's developers say the automated system could help standardize how pharmacists prepare tailored medications for pets.

The approval of Emeprev will help veterinary professionals by providing an in-clinic antiemetic option.

The monoclonal antibody from Zoetis previously received marketing authorization in Europe.

Six lots of Vetoquinol's Folltropin are affected.

The product is also indicated treatment and control of cattle fever tick.

The FDA’s new draft guidance outlines when monoclonal antibody developers can reduce or eliminate 6-month primate studies

Lindsay Hallman, CVT, CCMT, VTS (Oncology), and Katelyn McDonald, CVT, VTS (Oncology), discuss clinical administration of oncology therapy, in a dvm360 interview.

The single-injection monoclonal antibody (Lenivia) from Zoetis reduces OA pain in dogs for 3 months.

Lindsay Hallman, CVT, CCMT, VTS (Oncology), and Katelyn McDonald, CVT, VTS (Oncology), discuss what oncology patients may experience in a dvm360 interview.

Boehringer Ingelheim earned positive opinions for 2 immunization therapies in the pipeline.

OS Therapeutics' veterinary division is developing OST-HER2 for canine osteosarcoma treatment.

Gallant is developing FDA-regulated, off-the-shelf mesenchymal stromal cell therapies to rapidly modulate inflammation, support tissue repair, and make stem cell treatment broadly available to cats and dogs.

The study results place the American foulbrood prevention therapy closer to full USDA licensure.

This completion is a crucial requirement in the approval process for a drug.

Zoetis’ Vanguard Recombishield is a nonadjuvanted, recombinant injectable therapy.

Solovecin by Dechra is a generic antibiotic for the treatment of skin infections in dogs and cats.